No writing assistance was utilized in the production of this manuscript. Homozygous familial hypercholesterolemia is a rare but significant cause of early-onset coronary heart disease. Early ...

Escalated doses of lomitapide (5–10 mg/day; orally) with or without ezetimibe have been tested in patients with moderate hypercholesterolemia for a period of 12 weeks. The results indicated a ...

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a ...

Just 44% of eligible adults attended their midlife health check over the last five years - despite it cutting the risk of ...

The global market for point-of-care cholesterol monitoring devices is set for significant growth, with projections indicating ...

Patients with cryptogenic stroke treated with routine transcatheter patent foramen ovale closure have increased 4-year stroke risk.

Familial hypercholesterolemia is an inherited form of very high cholesterol that affects about 1 in 250 people. A gene mutation makes it harder for your liver to remove LDL cholesterol (the “bad ...

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology ...

Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...